Jump to content
Legal Wolverine

A drafting-table reading of the Wolverine blend — BPC-157 and TB-500 set down as two dimensioned components, the angiogenesis evidence drawn to scale, and the FDA, 503A and WADA access record kept in the title block.

SHEET A-09 / CORRESPONDENCE

Contact Legal Wolverine

Editorial questions, corrections, and sourcing notes about the BPC-157 TB-500 drafting sheet are welcome — a desk for the record, not a treatment service and not a sales channel.

Editorial inquiries only

Use the form to reach the editorial desk about the BPC-157 TB-500 digest. We read every message about a citation, a figure, a possible error, or a regulatory update we should reflect. If a study has been superseded, a DOI has moved, or the FDA record has changed, tell us and we will check it against the source.

What this desk is not: it is no clinic, no pharmacy, no prescriber, and no storefront. It cannot evaluate your health, recommend a dose, supply any peptide, or advise on obtaining the Wolverine blend, and it has no medical or legal advice to give. Questions of that kind belong with an appropriately licensed professional, not with an editorial project.

What to expect

We prioritize messages that improve the accuracy of the record: a miscited PMID, a number that does not match the source paper, a regulatory development we have not yet incorporated, or a place where the Wolverine legal status and 503A compounding page should be updated to reflect a new FDA action. Corrections grounded in a primary source are the fastest to act on.

We do not collect personal health information, and we ask that you do not send any. Keep inquiries to the editorial content itself — the studies, the citations, the regulatory status, and the way the blend's evidence is drawn on these pages. For the underlying sources, the Wolverine blend references page lists everything cited, with DOIs and PubMed or FDA links, so a correction can be checked against the primary record before we change anything on the sheet.